ArticleCancer immunology, immunotherapy : CII2023

Targeting GD2 after allogeneic SCT: effector cell composition defines the optimal use of ch14.18 and the bispecific antibody construct NG-CU (GD2-CD3).

A-M Arendt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.